David Ambinder, MD, is a urology resident at New York Medical College/Westchester Medical Center. His interests include surgical education, GU oncology, and advancements in technology in urology. A significant portion of his research has been focused on litigation in urology.
Studies on the use of cytoreductive nephrectomy in mRCC are reviewed, including its role among TKIs and immunotherapy.
Dr. Stacy Loeb is interviewed on the use of active surveillance for prostate cancer, its history, and new insights.
The utility of using AI to help determine scoring and surgical options for kidney cancer is examined against human scoring.
The current standard of care for patients with high-grade NMIBC, intravesical Bacillus Calmette-Guérin, is discussed.
Benjamin Davies, MD, gives his insight on how to reduce the use of opiates for patients after urologic surgery.
Active surveillance and enzalutamide monotherapy for localized prostate cancer is compared with active surveillance alone.
Reviewing a JAMA report on the effect of robot-assisted radical cystectomy in bladder cancer, along with the RAZOR trial.
An analysis of the HERO trial discussing the safety of relugolix, including major adverse cardiovascular events.
Dr. Ambinder discusses the use of focal therapy for prostate cancer and if it should be considered standard of care.